Mendez Carlos E, Walker Rebekah J, Dawson Aprill Z, Lu Kevin, Egede Leonard E
Division of General Internal Medicine, Department of Medicine, Froedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Diabetes and Endocrinology, Zablocki Veteran Affairs Medical Center, Milwaukee, Wisconsin; Center for Advancing Population Science (CAPS), Medical College of Wisconsin, Milwaukee, Wisconsin.
Division of General Internal Medicine, Department of Medicine, Froedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin; Center for Advancing Population Science (CAPS), Medical College of Wisconsin, Milwaukee, Wisconsin.
Endocr Pract. 2021 Aug;27(8):807-812. doi: 10.1016/j.eprac.2021.04.003. Epub 2021 Apr 19.
To assess the value of a validated diabetes risk test, the Cambridge Risk Score (CRS), to identify patients admitted to hospital without diabetes at risk for new hyperglycemia (NH).
This retrospective cross-sectional study included adults admitted to a hospital over a 4-year period. Patients with no diabetes diagnosis and not on antidiabetics were included. The CRS was calculated for each patient, and those with available glycated hemoglobin (HbA1C) results were investigated in a second analysis. Multivariate regression analyses were performed to assess the association among CRS, HbA1C, and the risk for NH.
A total of 19,830 subjects comprised the sample, of which 38% were found to have developed NH, defined as a blood glucose level ≥140 mg/dL. After accounting for covariates, the CRS was significantly associated with NH (odds ratio [OR], 1.19 [1.16, 1.22]; P < .001). Only 17% of patients had their HbA1C values checked within 6 months of admission. Compared with patients without diabetes, patients with prediabetes based on their HbA1C level (OR, 1.59 [1.37, 1.86]; P < .001) and patients with undiagnosed diabetes (OR, 5.95 [3.50, 10.65]; P < .001) were also significantly more likely to have NH.
Results of this study show that the CRS and HbA1C levels were significantly associated with the risk of developing NH in inpatient adults without diabetes. Given that an HbA1C level was missing in most medical records of hospitalized patients without diabetes, the CRS could be a useful tool for early identification and management of NH, possibly leading to better outcomes.
评估一种经过验证的糖尿病风险测试——剑桥风险评分(CRS),以识别因新发性高血糖(NH)而入院的非糖尿病患者。
这项回顾性横断面研究纳入了4年间入院的成年人。纳入无糖尿病诊断且未使用抗糖尿病药物的患者。为每位患者计算CRS,并在第二项分析中对有糖化血红蛋白(HbA1C)结果的患者进行研究。进行多变量回归分析以评估CRS、HbA1C与NH风险之间的关联。
共有19830名受试者组成样本,其中38%被发现发生了NH,定义为血糖水平≥140mg/dL。在考虑协变量后,CRS与NH显著相关(比值比[OR],1.19[1.16,1.22];P<.001)。只有17%的患者在入院后6个月内检查了HbA1C值。与无糖尿病患者相比,根据HbA1C水平诊断为糖尿病前期的患者(OR,1.59[1.37,1.86];P<.001)和未诊断出糖尿病的患者(OR,5.95[3.50,10.65];P<.001)发生NH的可能性也显著更高。
本研究结果表明,CRS和HbA1C水平与无糖尿病住院成年人发生NH的风险显著相关。鉴于大多数无糖尿病住院患者的病历中缺少HbA1C水平,CRS可能是早期识别和管理NH的有用工具,可能会带来更好的结果。